Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.44 |
| ▸ | MMP3 | P08254 | 11/20 | 0.43 |
| ▸ | MMP1 | P03956 | 8/20 | 0.43 |
| ▸ | MMP2 | P08253 | 7/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046183 | 0.85 | CTSL (0.46) | CTSSCTSLCTSBRENMMP3 | |
| SCHEMBL7044248 | 0.83 | CTSL (0.49) | CTSSCTSLCTSBMMP3MMP1 | |
| SCHEMBL7044867 | 0.83 | CTSS (0.48) | CTSSCTSLCTSBRENMMP3 | |
| SCHEMBL7109606 | 0.83 | CTSS (0.48) | CTSSCTSLCTSBRENMMP3 | |
| SCHEMBL6462673 | 0.81 | MEN1 (0.42) | CTSSCTSLCTSB | |
| SCHEMBL7049025 | 0.74 | CTSS (0.64) | CTSSCTSLCTSBRENMMP3 | |
| SCHEMBL7047934 | 0.73 | CTSS (0.46) | CTSSCTSLCTSBRENMMP3 | |
| SCHEMBL7045312 | 0.72 | CTSL (0.46) | CTSSCTSLCTSBMMP3MMP1 | |
| SCHEMBL7047000 | 0.72 | CTSS (0.42) | CTSSCTSLRENMMP3MMP1 | |
| SCHEMBL7043449 | 0.72 | CTSS (0.63) | CTSSCTSLCTSBRENMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSS 9/4885CTSL 18/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.